Suma Krishnan - Dec 11, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Suma Krishnan
Stock symbol
KRYS
Transactions as of
Dec 11, 2023
Transactions value $
-$5,283,291
Form type
4
Date filed
12/12/2023, 05:23 PM
Previous filing
Sep 12, 2023
Next filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$298K -2.85K -0.18% $104.26 1.6M Dec 11, 2023 Direct F1, F2
transaction KRYS Common Stock Sale -$477K -4.54K -0.28% $105.06 1.59M Dec 11, 2023 Direct F1, F3
transaction KRYS Common Stock Sale -$1.86M -17.5K -1.1% $106.04 1.57M Dec 11, 2023 Direct F1, F4
transaction KRYS Common Stock Sale -$10.8K -100 -0.01% $107.66 1.57M Dec 11, 2023 Direct F1
transaction KRYS Common Stock Sale -$459K -4.4K -0.27% $104.41 1.65M Dec 11, 2023 By Spouse F5, F6, F7, F8
transaction KRYS Common Stock Sale -$661K -6.26K -0.38% $105.50 1.65M Dec 11, 2023 By Spouse F5, F6, F8, F9
transaction KRYS Common Stock Sale -$1.51M -14.2K -0.86% $106.11 1.63M Dec 11, 2023 By Spouse F5, F6, F8, F10
transaction KRYS Common Stock Sale -$10.8K -100 -0.01% $107.66 1.63M Dec 11, 2023 By Spouse F5, F6, F8
holding KRYS Common Stock 90K Dec 11, 2023 By SMK Trust
holding KRYS Common Stock 50K Dec 11, 2023 By Krishnan Family Trust F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
F2 The transaction was executed in multiple trades ranging from $103.5600 to $104.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $104.5600 to $105.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $105.5600 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
F6 These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.
F7 The transaction was executed in multiple trades ranging from $103.9000 to $104.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8 Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
F9 The transaction was executed in multiple trades ranging from $104.9000 to $105.8900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 The transaction was executed in multiple trades ranging from $105.9000 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.